{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T23:55:33Z","timestamp":1779321333924,"version":"3.51.4"},"reference-count":21,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T00:00:00Z","timestamp":1639353600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["movementdisorders.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Evaluating the discrepancies between patient\u2010reported measures and clinician examination has implications for formulating individual treatment regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>This study investigated the association between health outcomes and level of self\u2010reported motor\u2010related function impairment relative to clinician\u2010examined motor signs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Recently diagnosed PD patients were evaluated using the Parkinson's Progression Marker Initiative (PPMI, N\u00a0=\u00a0420) and the PASADENA phase II clinical trial (N\u00a0=\u00a0316). We calculated the average normalized difference between each participant's part II and III MDS\u2010UPDRS (Movement Disorder Society Unified Parkinson's Disease Rating Scale) scores. Individuals with score differences &lt;25th or &gt;75th percentiles were labeled as low\u2010 and high\u2010self\u2010reporters, respectively (those between ranges were labeled intermediate\u2010self\u2010reporters). We compared a wide range of clinical\/biomarker readouts among these three groups, using Kruskal\u2013Wallis nonparametric and Pearson's \u03c7<jats:sup>2<\/jats:sup> tests. Spearman's correlations were tested for associations between MDS\u2010UPDRS subscales.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In both cohorts, high\u2010self\u2010reporters reported the largest impairment\/symptom experience for most motor and nonmotor patient\u2010reported variables. By contrast, these high\u2010self\u2010reporters were similar to or less impaired on clinician\u2010examined and biomarker measures. Patient\u2010reported nonmotor symptoms on MDS\u2010UPDRS part IB showed the strongest positive correlation with self\u2010reported motor\u2010related impairment (PPMI r<jats:sub>s<\/jats:sub>\u00a0=\u00a00.54, PASADENA r<jats:sub>s<\/jats:sub>\u00a0=\u00a00.52). This correlation was numerically stronger than the part II and clinician\u2010examined MDS\u2010UPDRS part III correlation (PPMI r<jats:sub>s<\/jats:sub>\u00a0=\u00a00.38, PASADENA r<jats:sub>s<\/jats:sub>\u00a0=\u00a00.28).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Self\u2010reported motor\u2010related impairments reflect not only motor signs\/symptoms but also other self\u2010reported nonmotor measures. This may indicate (1) a direct impact of nonmotor symptoms on motor\u2010related functioning and\/or (2) the existence of general response tendencies in how patients self\u2010rate symptoms. Our findings suggest further investigation into the suitability of MDS\u2010UPDRS II to assess motor\u2010related impairments. \u00a9 2021 The Authors. <jats:italic>Movement Disorders<\/jats:italic> published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society<\/jats:p><\/jats:sec>","DOI":"10.1002\/mds.28884","type":"journal-article","created":{"date-parts":[[2021,12,13]],"date-time":"2021-12-13T07:19:15Z","timestamp":1639379955000},"page":"585-597","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Self\u2010Report versus Clinician Examination in Early Parkinson's Disease"],"prefix":"10.1002","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2269-7473","authenticated-orcid":false,"given":"Sheida","family":"Zolfaghari","sequence":"first","affiliation":[{"name":"Integrated Program in Neuroscience McGill University  Montreal Quebec Canada"},{"name":"Research Institute of the McGill University Health Centre  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra E.","family":"Thomann","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Lewandowski","sequence":"additional","affiliation":[{"name":"Faculty of Science McGill University  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dylan","family":"Trundell","sequence":"additional","affiliation":[{"name":"Roche Products Limited  Welwyn Garden City United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Lipsmeier","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, pRED Informatics, Roche Innovation Center  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gennaro","family":"Pagano","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area  Basel Switzerland"},{"name":"King's College London  London United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirsten I.","family":"Taylor","sequence":"additional","affiliation":[{"name":"Roche Pharma Research and Early Development, Neuroscience and Rare Diseases Discovery and Translational Area  Basel Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald B.","family":"Postuma","sequence":"additional","affiliation":[{"name":"Research Institute of the McGill University Health Centre  Montreal Quebec Canada"},{"name":"Department of Neurology and Neurosurgery McGill University  Montreal Quebec Canada"},{"name":"Centre for Advanced Research in Sleep Medicine H\u00f4pital du Sacr\u00e9\u2010Coeur de Montr\u00e9al  Montreal Quebec Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,12,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S2006"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-6494.1987.tb00438.x"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1037\/0033-295X.96.2.234"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1037\/a0021715"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/0963721412439298"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1017\/CBO9780511819322.012"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1023279029852"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2004.52219.x"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2006.05.030"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/1385404049052412"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000058905.71369.97"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2014.00032"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1159\/000324935"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/arclin\/acx094"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09348-3"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2011.09.005"},{"key":"e_1_2_10_18_1","unstructured":"PaganoG BoessFG TaylorKI RicciB MollenhauerB&PoeweWet al. A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale design and baseline data. medRxiv. 2021:2021.04.09.21251911."},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10386"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijpor\/eds021"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22586"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s004150050131"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.28884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.28884","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.28884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:31:51Z","timestamp":1760970711000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.28884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,13]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["10.1002\/mds.28884"],"URL":"https:\/\/doi.org\/10.1002\/mds.28884","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,13]]},"assertion":[{"value":"2021-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}